Quick Answer
They suit different patients, and no trial has compared them, so there is no winner to declare. The discriminator is this: sermorelin is a shorter-acting, more physiologic single-agent GHRH analog given daily, while CJC-1295 with Ipamorelin pairs a long-acting GHRH analog with a selective growth hormone-releasing peptide acting at a second receptor, producing a sustained rather than a nightly signal. Which is appropriate is decided from your labs, your goals, your tolerance for daily injections and the cost of the program — by the prescribing physician.
This site already explains what sermorelin is, what CJC-1295 + Ipamorelin does, and how sermorelin compares with synthetic HGH — a drug this clinic does not prescribe. What it has never done is compare these two directly. That is this article. It assumes you know roughly what each one is.
One important caveat before the comparison: Vitality currently prescribes sermorelin, and does not currently offer CJC-1295 + Ipamorelin. CJC-1295 is not authorised for compounding by a licensed 503A pharmacy, and ipamorelin remains on the FDA's Category 2 list. Both are covered here because patients ask about them constantly and the comparison is genuinely useful, but the second protocol is described for education, not offered as a service. The regulatory detail is at the end of this article.
The Comparison
| Factor | Sermorelin | CJC-1295 + Ipamorelin |
|---|---|---|
| Mechanism | A single agent: a synthetic analog of growth hormone-releasing hormone (GHRH), prompting the pituitary to release its own growth hormone. | Two agents: a long-acting GHRH analog paired with a selective growth hormone-releasing peptide (GHRP), stimulating the same cells by two routes at once. |
| Receptors acted on | GHRH receptor only. | GHRH receptor (CJC-1295) plus the GHRP / ghrelin receptor (Ipamorelin). |
| Duration of action and dosing frequency | Short. GHRH's brief duration of action is the specific limitation the long-acting analogs were developed to overcome. Given daily, usually in the evening. | Long. In healthy adults the estimated half-life of CJC-1295 was 5.8–8.1 days, and a single injection raised growth hormone 2- to 10-fold for six days or more. Dosed far less often. |
| Physiologic / pulsatile profile | Closer to the body's own pattern — a short signal given when the axis is naturally most active. | Sustained elevation rather than a single evening pulse. After repeated doses, mean IGF-1 stayed above baseline for up to 28 days. |
| Cortisol and prolactin selectivity | Acts on the GHRH receptor, so the cortisol question does not arise in the same way. | Ipamorelin was the first GHRP-receptor agonist shown to release growth hormone without raising ACTH or cortisol — unlike GHRP-6 and GHRP-2, which did. Prolactin was unaffected by any of the agents tested. Demonstrated in rat and swine models, not in humans. |
| Human evidence base | Thinner than its reputation. Widely used and long-established in physician-supervised practice, but the frequently cited sermorelin reference is a two-page commentary rather than a trial, and long-term data in healthy adults is limited. | Better than most patients expect on pharmacokinetics: two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults, lasting 28 and 49 days. Pharmacokinetics is not clinical outcomes, and outcome trials are absent for both. |
| Patients Dr. Jaqua tends to consider it for | Patients who want the more physiologic single-agent option, who are comfortable with a daily injection, and whose IGF-1 and clinical picture suggest a modest nudge is what is needed. | Patients for whom daily injections are the thing most likely to derail adherence, or whose response to a single-agent GHRH analog has been insufficient on labs. |
| What drives the cost | Daily dosing means more medication over a program, offset by a single compounded agent. | Two compounded agents, but far fewer administrations. Which works out cheaper depends on the program length and the preparation, not on a headline price. |
| Regulatory status | Prescribed off-label, compounded by a licensed 503A pharmacy, and it has not received drug approval from the FDA for the uses described. | Prescribed off-label, compounded by a licensed 503A pharmacy, and both agents were named in the February 27, 2026 HHS reclassification announcement. Neither has FDA drug approval for these uses. |
The duration-of-action and IGF-1 figures above come from the two randomized, placebo-controlled trials of CJC-1295 in healthy adults, which reported an estimated half-life of 5.8–8.1 days, growth hormone raised 2- to 10-fold for six days or more, IGF-1 raised 1.5- to 3-fold for nine to eleven days, and IGF-1 remaining above baseline for up to 28 days after multiple doses.1 Those same authors framed the whole problem in one line: therapeutic use of GHRH is limited by its short duration of action.1 That sentence is the entire reason both protocols exist in the form they do.
One practical warning about the name.Preparations sold as “CJC-1295” are not all the same molecule, and duration of action differs substantially between them. If you are comparing quotes between clinics, ask which preparation is being compounded and how often it is dosed, because the answer changes what you are actually buying.
Why Ipamorelin Specifically
The second agent is where the pairing earns its place. Growth hormone-releasing peptides act on a different receptor from GHRH, so adding one to a GHRH analog stimulates the same pituitary cells by two independent routes. The problem with the older GHRPs was collateral damage: GHRP-6 and GHRP-2 also raised ACTH and cortisol.
Ipamorelin was developed to avoid that, and did. In the study that introduced it, ipamorelin released growth hormone with potency and efficacy comparable to GHRP-6, but did not raise ACTH or cortisol even at doses more than 200-fold above the dose producing half-maximal growth hormone release — while GHRP-6 and GHRP-2 both did. None of the agents tested affected prolactin, LH, FSH or TSH.2
The caveat belongs in the same breath: that work was done in rat pituitary cells, anaesthetised rats and conscious swine. It is a strong preclinical selectivity result, not a human trial, and it should be described as what it is.
Who Each One Tends to Suit
These are tendencies from clinical practice, not a self-selection quiz. Nobody should read this section and conclude which protocol they need.
Sermorelin is often the starting point where the aim is the most physiologic intervention available — a short evening signal to an axis that is naturally most active during early sleep, in a patient whose IGF-1 suggests a nudge rather than a push. It is a single compounded agent, which keeps the protocol simple, and daily administration means a change can be made and felt quickly.
CJC-1295 + Ipamorelin tends to come up where daily injections are the realistic obstacle, or where a single-agent GHRH analog has not moved IGF-1 in a patient who has been taking it properly. Sustained elevation is the trade: fewer administrations, less of the natural nightly pattern.
Adherence deserves more weight than it usually gets. A weekly protocol taken as prescribed will outperform a daily protocol taken four nights out of seven, and it is worth being honest with your physician about which you are.
What Both Have in Common
Almost everything that matters, in fact:
- Neither is HGH.Both act upstream on the patient's own pituitary rather than delivering growth hormone from outside. The distinction, and why it matters, is in sermorelin vs HGH.
- Both are prescribed off-label and compounded by a licensed 503A pharmacy. Neither has received drug approval from the FDA for the uses described.
- Both are monitored on IGF-1, alongside glucose handling, because growth hormone opposes insulin.
- Both share the same side-effect profile in kind — injection-site reactions, fluid retention, joint discomfort — and the same review of growth hormone secretagogue safety and efficacy covers both classes.3
- Neither has outcome trials in this population. There is human pharmacokinetic data, a physiologic rationale,4 and clinical experience. There is no trial telling you what either does to body composition, sleep or recovery in healthy adults over years.
What It Costs, and Why That Is Not a Number Here
Cost is driven by dosing frequency, the compounding involved, and how long the program runs — not by which peptide sounds more advanced. A daily single agent and a weekly two-agent protocol can land in similar territory over a year, and the ordering depends on the specific preparation. The components are broken down in how much does peptide therapy cost.
How the Choice Is Actually Made
Labs first. Baseline IGF-1, glucose handling, thyroid function, a complete blood count and whatever else the clinical picture calls for. Then symptoms, read against those numbers rather than instead of them. Then the practical questions: what else you are taking, what you are treating, and how the injection schedule fits a real week.
That decision belongs to the prescriber, and at Vitality it is not delegated — Dr. Jaqua reads the panel and writes the protocol herself. The two product pages, sermorelin and CJC-1295 + Ipamorelin, cover each protocol in its own right.
One closing note, because it is the most useful thing on this page: the available evidence does not support a blanket claim that either protocol is superior, and this article deliberately does not make one. If a clinic tells you one of these is simply better, ask them which trial says so.
Frequently Asked Questions
Which one works better?
No trial has compared them head to head, so there is no honest answer to that question and any clinic giving you one is guessing. The real question is which suits you: how your IGF-1 and clinical picture look, whether you will realistically take a daily injection, what else you are being treated for, and what the program costs over its length. That is a physician's decision made from labs.
Can I switch from one to the other?
Yes, and it is fairly common. A switch is usually prompted by labs that have not moved, adherence that is not holding, or a side effect. It is a prescribing change with a fresh look at IGF-1 afterwards, not something to be done between appointments.
Can they be combined?
CJC-1295 and Ipamorelin already are a combination — that is what the protocol is. Adding sermorelin on top of a GHRH analog you are already taking is stimulating the same receptor twice, which is a physician's decision and not something a patient should assemble. Bring it up at consultation rather than acting on it.
Which is cheaper?
It depends on the program rather than on a sticker price. Sermorelin is a single compounded agent given daily; CJC-1295 + Ipamorelin is two agents given much less often. Total cost turns on dosing frequency, compounding and program duration, which is why pricing is reviewed at consultation for the actual protocol rather than published as a headline figure.
Does one raise IGF-1 more?
CJC-1295 produces a longer and more sustained IGF-1 elevation — in healthy adults, a single injection raised IGF-1 1.5- to 3-fold for nine to eleven days, and repeat dosing kept it above baseline for up to 28 days. Whether more sustained is better is a different question, and it is the one that has no trial answer. Higher IGF-1 is not automatically the goal, which is why the number is monitored rather than maximized.
Is either of them HGH?
No. Neither contains growth hormone. Both act upstream, prompting your own pituitary to release it, which is a different thing from injecting synthetic growth hormone. That distinction is set out in our sermorelin vs HGH article.
References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006;91(3):799–805. DOI: 10.1210/jc.2005-1536
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998;139(5):552–561. Selectivity demonstrated in rat pituitary cells, rats and swine, not in humans. DOI: 10.1530/eje.0.1390552
- Sigalos JT, Pastuszak AW. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sex Med Rev. 2018;6(1):45–53. DOI: 10.1016/j.sxmr.2017.02.004
- Walker RF. “Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?” Clin Interv Aging.2006;1(4):307–308. A two-page commentary, cited for the physiologic argument rather than as trial evidence. PMID: 18046908
This article is general information and is not medical advice, and it contains no dosing instructions. Both protocols are prescribed off-label at physician discretion following individual evaluation and have not received drug approval from the FDA for the uses described.